News >

Molecular Testing Continues to Evolve in Ovarian Cancer

Ellie Leick
Published: Friday, Jul 19, 2019

Jubilee Brown, MD, a professor of gynecologic oncology at Levine Cancer Institute, Atrium Health

Jubilee Brown, MD

As PARP inhibitors have showcased a survival benefit in select patients with ovarian cancer, Jubilee Brown, MD, explains that there must be a widespread approach to conduct molecular testing in all patients with the disease to provide them with a personalized treatment approach.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication